



Berkshire West Area Prescribing Committee

Drug Name	Naproxen with esomeprazole (Vimovo®)		
Indication under review	The relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis		
Policy No:	APC 065		
Date of Issue/ Date of re-issue:	January 2014/ March 2017		
Review Date:	March 2020		
Policy Statement:	Naproxen with esomeprazole (Vimovo®) is not recommended for the routine treatment of patients with signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.		
Traffic Light Status	Brown		
Key Points considered:	<ul style="list-style-type: none"> • Vimovo® treatment does not have significant benefits other treatments. • Not considered to be cost effective given the price difference between this combination product and separate combinations of naproxen and proton pump inhibitors. • This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget. 		
References:	<ol style="list-style-type: none"> 1. Osteoarthritis: National clinical guideline for care and management in adults. National Collaborating Centre for Chronic Conditions http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf 2. CG79 Rheumatoid arthritis: full guideline. February 2009. NICE http://www.nice.org.uk/nicemedia/live/12131/43326/43326.pdf 3. Summary of product characteristics: Vimovo 500mg/20mg modified-release tablets. AstraZeneca UK Limited www.emc.medicines.org.uk 4. Horberg M, Fort J, svensson O, Hwang C, Sostek M. Fixed dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med research & opinion Vol 27 No.6, 2011, 1243-1253 5. P. Miner Jr*, J. Plachetka, E. Orlemans, J. G. Fort & M. Sostek. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers. AP & T. 		
Date taken to APC:	1 st March 2017		
Date Ratified by GP MOC on Behalf of the Board:	15 th March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only